

Atopic Dermatitis Autoimmune Disorder

A study to look at the effects of a new medicine (astegolimab) in comparison to placebo - in patients with eczema (atopic dermatitis)

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

Trial Status Completed	Trial Runs In 3 Countries	Trial Identifier NCT03747575 2018-003429-27 GS40965
----------------------------------	-------------------------------------	--

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD). The study consists of a screening period, a 16-week treatment period, and an 8-week follow-up period.

Genentech, Inc. Sponsor	Phase 2 Phase
-----------------------------------	-------------------------

NCT03747575 2018-003429-27 GS40965
Trial Identifiers

Eligibility Criteria:

Gender All	Age >= 18 Years & <= 75 Years	Healthy Volunteers No
----------------------	---	---------------------------------

This clinical trial was done to study a new medicine called, “astegolimab”, for the treatment of patients with “eczema (atopic dermatitis)”. This study was done to find out if astegolimab – a new medicine – was effective for treating patients with a certain type of eczema (atopic dermatitis). Sixty-five patients took part in this study at 21 study centers in 3 countries.